FDA Approves DifGen's Generic Epinephrine Injection, Second Adrenalin Rival in US
核心洞察
The FDA has approved DifGen Pharmaceuticals' ANDA for Epinephrine Injection USP, 1 mg/mL single-dose vials, the second generic version of Adrenalin Injection.
The product is bioequivalent and therapeutically equivalent to the reference listed drug Adrenalin Injection, 1 mg/mL, held under NDA 204200.
DifGen said the approval adds another source of the emergency medicine for the US market and advances its sterile injectable portfolio strategy.
DifGen Pharmaceuticals LLC said the U.S. Food and Drug Administration (搜索) has approved its Abbreviated New Drug Application for Epinephrine Injection USP, 1 mg/mL, in single-dose vials. The Miramar, Florida-based specialty generic manufacturer announced the approval on Sept. 16, 2026.
The approved product is bioequivalent and therapeutically equivalent to the reference listed drug Adrenalin Injection, 1 mg/mL (NDA 204200). According to DifGen, its version is the second generic approval referencing that product, which adds another supply source of the injectable emergency medicine for the U.S. market.
Regulatory Basis and Product Details
The approval was granted through the ANDA pathway, which relies on demonstrating bioequivalence to an already approved reference product rather than submitting new clinical efficacy data. DifGen states that its Epinephrine Injection USP, 1 mg/mL is supplied in single-dose vials and has been cleared by the FDA as bioequivalent and therapeutically equivalent to Adrenalin Injection, 1 mg/mL, of PH Health Limited (搜索).
The company directs prescribers to the approved prescribing information for complete details on indications, dosage and administration, contraindications, warnings and precautions, and adverse reactions. Adrenalin is a registered trademark of its respective owner, and DifGen notes it is not affiliated with the brand product's owner.
Portfolio Strategy in Sterile Injectables
DifGen framed the approval as part of a broader effort to build a differentiated injectable portfolio for the U.S. market, with a focus on medicines it considers important to hospitals, healthcare providers and patients. The company said epinephrine is an important emergency medicine used in acute clinical settings.
The company describes an integrated approach spanning product selection, formulation and process development, regulatory execution, manufacturing and commercialization, aimed at providing a reliable supply of high-quality medicines to the U.S. healthcare market. DifGen said the approval reflects continued investment in complex and differentiated products across multiple dosage forms, including sterile injectables.
DifGen Pharmaceuticals LLC develops, manufactures and commercializes pharmaceutical products for the U.S. and international markets, with a portfolio spanning complex generics, specialty pharmaceuticals and differentiated dosage forms.